OCE Oncology News
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
Lauren E. Nye, MD, discusses how the expansion of targeted therapies in metastatic hormone receptor–positive breast cancer has shifted management approaches.
CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.
Anne Chiang, MD, PhD, discusses understanding the heterogeneity of SCLC to determine which patients will respond to targeted therapy.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.
Apple cider vinegar, a liquid made from fermenting apples, is said to have many potential health benefits. But what does research say about these claims?…
Axel Hauschild, MD, elucidates the varying role of treatment for both cutaneous cell carcinoma and basal cell carcinoma that are seen globally.
An abstract is unavailable.
Melanoma risks and prevention in people of color: Understand the critical role of awareness, early detection, and the necessity of skin checks.
TNO155 combined with either spartalizumab or ribociclib showed acceptable safety and tolerability across solid tumors in a phase 1b open-label study.